[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100583544":3},{"organization":4,"armGroups":7,"interventions":35,"overallOfficials":41,"centralContacts":11,"locations":44,"responsibleParty":58,"collaborators":11,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":11,"eligibilityCriteria":66,"healthyVolunteers":67,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":11,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":82,"whyStopped":11,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Bristol-Myers Squibb","INDUSTRY",[8,14,17,20,23,26,29,32],{"label":9,"type":10,"description":11,"interventionNames":12},"Part 1: Sequence 1","EXPERIMENTAL",null,[13],"Drug: BMS-986460",{"label":15,"type":10,"description":11,"interventionNames":16},"Part 1: Sequence 2",[13],{"label":18,"type":10,"description":11,"interventionNames":19},"Part 1: Sequence 3",[13],{"label":21,"type":10,"description":11,"interventionNames":22},"Part 2: Treatment A",[13],{"label":24,"type":10,"description":11,"interventionNames":25},"Part 2: Treatment B",[13],{"label":27,"type":10,"description":11,"interventionNames":28},"Part 2: Optional Treatment C",[13],{"label":30,"type":10,"description":11,"interventionNames":31},"Part 2: Optional Treatment D",[13],{"label":33,"type":10,"description":11,"interventionNames":34},"Part 2: Optional Treatment E",[13],[36],{"type":37,"name":38,"description":39,"armGroupLabels":40,"otherNames":11},"DRUG","BMS-986460","Specified dose on specified days.",[9,15,18,27,30,33,21,24],[42],{"name":5,"affiliation":5,"role":43},"STUDY_DIRECTOR",[45],{"facility":46,"status":11,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":11},"Local Institution - 0001","Lenexa","Kansas","66219","United States","US",{"type":53,"coordinates":54},"Point",[55,56],-94.73357,38.95362,{"lat":56,"lon":55},{"type":59,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100583544","phase-1-a-single-dose-study-to-evaluate-the-safety-tolerability-drug-levels-and-relative-biological-availability-of-alternate-formulations-of-bms-986460-in-healthy-adult-male-participants-100583544",false,"NCT06877702","A Single-dose Study to Evaluate the Safety, Tolerability, Drug Levels, and Relative Biological Availability of Alternate Formulations of BMS-986460 in Healthy Adult Male Participants","A Phase 1, 2-Part, Open-label Study to Evaluate Relative Bioavailability of Alternate Formulations of BMS-986460 in Healthy Adult Male Participants (Part 1), and a Single Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of BMS-986460 in Healthy Adult Male Participants (Part 2)","Inclusion Criteria\n\n* Participants must be healthy as determined by no clinically significant deviation from normal in medical history, physical examination, vital signs, 12-lead ECGs, echocardiogram or clinical laboratory assessments, as determined by the investigator.\n* Participants must have a Body mass index (BMI) between 18.0 and 35.0 kilograms\u002Fmeter square (kg\u002Fm2), inclusive.\n* Male participants who are sexually active with individuals of childbearing potential (IOCBP) must agree to follow instructions for methods of contraception.\n\nExclusion Criteria:\n\n* Participants with prior exposure to BMS-986460 or with a prior history of heart failure, ischemic heart diseases, clinically significant cardiac arrythmias, or long QT syndrome are excluded.\n* Participants with left ventricular ejection fraction (≤ 50%) at screening are excluded.\n* Participants with history of anaphylactic reactions are excluded.\n* Participants with current or recent (within 3 months of intervention administration) gastrointestinal disease that, in the opinion of the investigator, could affect the absorption of study intervention are excluded.\n* Participants with history of Gilbert's syndrome are excluded.\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.",true,"MALE","18 Years","60 Years",{"count":72,"type":73},85,"ACTUAL","INTERVENTIONAL",[76],"PHASE1","The purpose of this study is to assess the safety, tolerability, drug levels, and relative bioavailability of alternate formulations of BMS-986460 in healthy adult male participants.",[79],"Healthy Volunteers",[81],"BMS-986460, bioavailability, healthy adult male, crossover, SAD","COMPLETED","2026-01-16",{"date":85,"type":73},"2026-01-20",{"date":87,"type":73},"2025-03-19",{"date":89,"type":73},"2025-12-17",{"name":5,"class":6},1]